

## Draft Guidance on Valbenazine Tosylate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Valbenazine tosylate

**Dosage Form; Route:** Capsule; oral

**Recommended Studies:** Two studies

1. Type of study: Fasting  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 80 mg (BASE)  
Subjects: Males and non-pregnant, non-lactating females, general population

Additional comments: Women should not breastfeed during the study and for 5 days after the final dose.

- 
2. Type of study: Fed  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 80 mg (BASE)  
Subjects: Males and non-pregnant, non-lactating females, general population

Additional comments: Please see above

---

**Analytes to measure in plasma:** Valbenazine and its active metabolite  $\alpha$ -dihydrotrabenazine

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and  $C_{max}$ .

**Bioequivalence based on (90% CI):** Valbenazine

**Waiver request of in vivo testing:** 40 mg (BASE) based on (i) acceptable bioequivalence studies on the 80 mg strength (BASE), (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the

public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>.  
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).